COVID-19: Labatec update

Published on 5 May 2020 dans

In line with our historic commitment to our healthcare partners, Labatec is continuing to multiply its efforts to help our customers and patients navigate the challenges of the COVID-19 pandemic. Now more than ever, we are taking action to ensure that our supply of essential medicines particularly used to treat COVID-19 patients remains uninterrupted despite the extremely high demand we are facing and the disruptions affecting global supply chains.

While many other Pharma companies are facing stock-outs across Switzerland, we have taken extraordinary internal measures to ensure that an emergency supply of COVID-19 products such as pain, sedatives, anaesthetics and anti-infective medicines continues to reach the Swiss hospitals. Our teams are working under strict hygiene measures and remain in daily virtual contact with COVID-19 clinics and hospitals to follow and respond to this evolving demand as closely as possible. This work is being done in close collaboration with the Swiss Federal Office for Public Health.

In addition to its supply of COVID-19 essential medicines, Labatec is drawing on its cross-regional footprint to help our healthcare partners respond to this crisis by sharing experience and information across countries. We have successfully run a webinar connecting a leading Swiss infectious diseases specialist with over 700 Doctors and HCPs across the MENA region to discuss learnings from Swiss COVID crisis management strategies. We are convinced that disseminating such learnings and information will lead to a more effective response globally.

We are proud of the essential role we play in helping to manage this unprecedented health crisis globally, and will continue to do so while ensuring that we take all necessary precautions to minimize  the risks to our employees’ health in the workplace.

Get in touch

Would you like to discuss a collaboration or partnership project? Get in touch with us at or connect with us at one of the upcoming events.

For other enquiries, please visit our contact page.